Physician profile
Maanvi Kumar
NPI 1548658545
$1,486.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $280 · 2021: $171 · 2022: $72.57 · 2023: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $222.14 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $175.59 | 2019 | |
| Supernus Pharmaceuticals, INC. | $170.85 | 2021 | |
| Abbvie INC. | $134.23 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $119.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $114.71 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $103.66 | 2019-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $100.46 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $69.62 | 2019 | |
| Lundbeck LLC | $53.42 | 2019-2023 | Rexulti |
| Adlon Therapeutics L.P. | $48.13 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $45.28 | 2019-2020 | |
| Shire North American Group INC | $39.91 | 2019 | |
| Neuronetics, INC. | $30.12 | 2023 | Neurostar Tms Therapy System |
| Validus Pharmaceuticals LLC | $26.65 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.92 | 2019 | |
| Alkermes, INC. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maanvi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.